2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
In our exclusive interview, David R. Gandara, MD highlights the benefits and challenges of delivering patient care virtually and its reception among patients, discusses the sustainability of virtual CME platforms and forecasts what the “new normal” of oncology education may look like as a result of the pandemic.
Welcome to a very special edition of OncLive On Air™! I’m your host today, Jessica Hergert.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
Today, we had the pleasure of speaking with David R. Gandara, MD, director of the Thoracic Oncology Program, professor, and senior advisor to the director at the University of California Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care® in Lung Cancer, to discuss the impact that the coronavirus disease 2019 (COVID-19) pandemic has had on the treatment of patients with cancer and the ways in which the medical community has kept continuing medical education (CME) alive during an era that necessitates social distancing.
In our exclusive interview, Gandara highlighted the benefits and challenges of delivering patient care virtually and its reception among patients, discussed the sustainability of virtual CME platforms and forecasted what the “new normal” of oncology education may look like as a result of the pandemic.